Infectious Diseases最新文献_第4页

Pitfalls of SARS-CoV-2 antigen testing at emergency department 急诊科严重急性呼吸系统综合征冠状病毒2型抗原检测的缺陷

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-30 DOI: 10.1080/23744235.2022.2083226

Eleonora Cottone, F. Van Hoecke, G. Martens, E. De Laere, Roos De Smedt, Steven Vervaeke, M. Vanhee, D. De Smet

{"title":"Pitfalls of SARS-CoV-2 antigen testing at emergency department","authors":"Eleonora Cottone, F. Van Hoecke, G. Martens, E. De Laere, Roos De Smedt, Steven Vervaeke, M. Vanhee, D. De Smet","doi":"10.1080/23744235.2022.2083226","DOIUrl":"https://doi.org/10.1080/23744235.2022.2083226","url":null,"abstract":"Abstract Background Current method for diagnosis of SARS-CoV-2 infection is an RT-PCR test on the nasopharyngeal or oropharyngeal swab. Rapid diagnosis is essential for containing viral spread and triage of symptomatic patients presenting to hospital ER departments. As a faster alternative to RT-PCR, we evaluated a SARS-Cov-2 Rapid Antigen test in symptomatic patients presenting to hospital ER departments. Methods We evaluated the diagnostic performance of the Roche SARS-CoV-2 Rapid Antigen test (SD Biosensor) for detection of SARS-CoV-2 compared to RT-PCR. Results Our study showed inferior performance of the SARS-CoV-2 Rapid Antigen test for detection of SARS-CoV-2. Firstly, because of the lack of specificity, which is potentially life-threatening due to the association of nosocomial-acquired SARS-CoV-2 infection. Secondly, with a sensitivity of 45.5%, it is impossible to rule out SARS-CoV-2 infection, resulting in reflex PCR-testing. Comparison of viral load in RT-PCR positive samples with corresponding antigen results showed a significant difference between antigen positive and negative samples. COVID-19 infection will not be detected in patients admitted to the hospital in an early or late phase, typically associated with low viral loads. Sensitivity increases when testing within 5–7 symptomatic days, but the implementation of this cut-off is impractical in ER settings. However, diagnostic performance is better to detect high viral load (> = 5 log10 copies/mL) linked with contagiousness. Conclusion Our study showed inferior performance of the Roche SARS-CoV-2 Rapid Antigen test (SD Biosensor) for detection of SARS-CoV-2 which limits its use as a diagnostic gatekeeper in ER departments, but is able to differentiate contagious individuals.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"731 - 737"},"PeriodicalIF":5.8,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43452595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of patients with infective endocarditis and no underlying cardiac conditions 无潜在心脏疾病的感染性心内膜炎患者的特点

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-23 DOI: 10.1080/23744235.2022.2078404

Aleyya Radjabaly Mandjee, L. Filippetti, F. Goehringer, X. Duval, E. Botelho-Nevers, C. Tribouilloy, R. Huguet, C. Chirouze, M. Erpelding, B. Hoen, C. Selton-Suty, Agrinier Nelly, B. Lefèvre

{"title":"Characteristics of patients with infective endocarditis and no underlying cardiac conditions","authors":"Aleyya Radjabaly Mandjee, L. Filippetti, F. Goehringer, X. Duval, E. Botelho-Nevers, C. Tribouilloy, R. Huguet, C. Chirouze, M. Erpelding, B. Hoen, C. Selton-Suty, Agrinier Nelly, B. Lefèvre","doi":"10.1080/23744235.2022.2078404","DOIUrl":"https://doi.org/10.1080/23744235.2022.2078404","url":null,"abstract":"Abstract Background Infective endocarditis (IE) typically occurs in patients with underlying cardiac conditions (UCC). Little is known about IE in patients without UCC. We aimed to describe the clinical, microbiological and imaging characteristics, management, and in-hospital mortality of IE patients without UCC. Methods We analysed the data of patients with definite IE included in an observatory between 1st January 2009 and 31st December 2019. We described patients without UCC compared to those with UCC. Results Of 1502 IE patients, 475 (31.6%) had no UCC. They were younger (median 64.0 [19.0–101.0] vs. 70.0 [18.0–104.0] years, p < .001), more often on chronic haemodialysis (5.5% vs. 2.7%, p = .008), and had more often malignancy (22.5% vs. 17.3%, p = .017), immune deficiency (10.3% vs. 6.4%, p = .008), and an indwelling central venous line (14.5% vs. 7.0%, p < .001). They more often developed cerebral complications (34.7% vs. 27.5%, p = .004) and extracerebral embolism (48.6% vs. 36.1%, p < .001). Causative microorganisms were less often coagulase negative staphylococci (5.9% vs. 10.8%, p = .002) or enterococci (10.3% vs. 15.0%, p = .014) and more often group D streptococci (14.1% vs. 10.0%, p = .020). Vegetations were more common (92.8% vs. 77.0%, p < .001) and larger (14.0 [1.0–87.0], vs. 12.0 [0.5–60.0] mm, p = .002). They had more valve perforation or valve regurgitation (67.4% vs. 53.0%, p < .001) and underwent valve surgery more often (53.5% vs. 36.3%, p < .001). In-hospital mortality did not significantly differ between groups. Conclusion Patients with IE and no UCC were younger than those with UCC, had specific comorbidities and portals of entry, and a more severe disease course.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"656 - 665"},"PeriodicalIF":5.8,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45065697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Antibiotic prescribing among elderly living in long-term care facilities versus elderly living at home: a Danish registry-based study 长期护理机构老年人与居家老年人的抗生素处方：一项基于丹麦注册的研究

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-19 DOI: 10.1080/23744235.2022.2076903

Hadir Azaizi, Maria Louise Veimer Jensen, Ida Scheel Rasmussen, J. Jarløv, Jette Nygaard Jensen

{"title":"Antibiotic prescribing among elderly living in long-term care facilities versus elderly living at home: a Danish registry-based study","authors":"Hadir Azaizi, Maria Louise Veimer Jensen, Ida Scheel Rasmussen, J. Jarløv, Jette Nygaard Jensen","doi":"10.1080/23744235.2022.2076903","DOIUrl":"https://doi.org/10.1080/23744235.2022.2076903","url":null,"abstract":"Abstract Background The objective of this study was to compare antibiotic prescription rates in Denmark among elderly living in long-term care facilities to elderly living at home, with regards to total antibiotic use and antibiotic use for urinary tract infection. Methods This is an observational registry-based study. The study population included all elderly Danish residents aged ≥75 years in 2016. Linear regression models were used to examine the difference in antibiotic prescription rates between elderly living in long-term care facilities and elderly living at home. Results were adjusted for age, sex and comorbidity, the latter assessed via the Charlson Comorbidity Index. Results The study population consisted of 416,627 elderly. Regression models showed that elderly living in long-term care facilities were prescribed 1.7 [CI 1.7–1.7] prescriptions/individual/year more than elderly living at home. For urinary tract infections the difference between elderly living in long-term care facilities and elderly living at home was 1.2 [CI 1.2–1.3] prescriptions/individual/year. Conclusions Elderly living in long-term care facilities have a higher antibiotic prescribing rate than elderly living at home, despite controlling for age, sex and comorbidity. This indicates that long-term care facilities continuously should be a focus for antibiotic stewardship interventions.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"651 - 655"},"PeriodicalIF":5.8,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45737570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Recombinant parechovirus A3 possibly causes various clinical manifestations, including myalgia; findings in Yamagata, Japan in 2019 重组parechovirus A3可能引起多种临床表现，包括肌痛;2019年在日本山形的研究结果

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-17 DOI: 10.1080/23744235.2022.2069857

K. Mizuta, T. Itagaki, Shuji Chikaoka, M. Wada, Toru Ikegami, D. Sendo, C. Iseki, Y. Shimizu, S. Abe, K. Komabayashi, Y. Aoki, T. Ikeda

{"title":"Recombinant parechovirus A3 possibly causes various clinical manifestations, including myalgia; findings in Yamagata, Japan in 2019","authors":"K. Mizuta, T. Itagaki, Shuji Chikaoka, M. Wada, Toru Ikegami, D. Sendo, C. Iseki, Y. Shimizu, S. Abe, K. Komabayashi, Y. Aoki, T. Ikeda","doi":"10.1080/23744235.2022.2069857","DOIUrl":"https://doi.org/10.1080/23744235.2022.2069857","url":null,"abstract":"Abstract Background Parechovirus A3 was first reported in 2004 and has been recognized as a causative agent of mild and severe infections in children. Since we first reported an outbreak of adult parechovirus A3-associated myalgia in Yamagata, Japan in 2008, this disease has since been recognized across Japan, but has not yet been reported from other countries. Aim We analysed 19 cases of parechovirus A3 infections identified in Yamagata in 2019 to further clarify the epidemiology of this disease. Methods We performed phylogenetic analyses of parechovirus A3 isolates and analysed the clinical manifestations and the genomic clusters. Results There were two clusters, with cluster 2019B replacing 2019 A around October/November. Phylogenetic analysis revealed that 2019B cluster strains and Australian recombinant strains, which appeared between 2012 and 2013, were grouped in one cluster at non-structural protein regions, suggesting that the ancestor to these regions of 2019B cluster strains were Australian recombinant lineage strains. The strains from both clusters caused various infections in children including myalgia. These findings strongly support that parechovirus A3 strains cause myalgia and other paediatric infections irrespective of the virus strains involved, including recombinant strains.　　 Conclusions We have reported repeatedly sporadic cases of myalgia and here showed that recombinant strains also cause myalgia. We hope our experiences will help better understand these infections and possibly result in detection of more cases in the world.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"632 - 650"},"PeriodicalIF":5.8,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42237811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination 1例腺病毒covid-19载体疫苗可能与接种后严重但可逆的间质性肺损伤有关

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-12 DOI: 10.1080/23744235.2022.2072521

G. Liatsos, A. Mavroudis, P. Iliakis, M. Karmpalioti, E. Koullias, D. Vassilopoulos

{"title":"A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination","authors":"G. Liatsos, A. Mavroudis, P. Iliakis, M. Karmpalioti, E. Koullias, D. Vassilopoulos","doi":"10.1080/23744235.2022.2072521","DOIUrl":"https://doi.org/10.1080/23744235.2022.2072521","url":null,"abstract":"Abstract Background Several safe and effective vaccines against nCoV-19 have been developed to contain the pandemic with very few severe adverse-reactions reported. Vaccine-induced interstitial lung disease (ILD) is a very rare and difficult to recognise and diagnose adverse-reaction and is mostly associated with Influenza vaccines. Methods We report a 55-yr old male who presented with severe respiratory failure that required for several days oxygen supplementation with high flow nasal cannula, and myocardial infarction. Symptoms onset was eighteen days after the first shot of adenoviral AZD1222 vector vaccine. Possible SARS-CoV-2 natural infection post-vaccination was excluded with rigorous laboratory work-up including multiple nasopharengeal rt-qPCR tests for SARS-CoV-2 detection and close monitoring of his serum SARS-CoV-2 antibodies. Other potential infectious agents and alternate diagnoses were thoroughly investigated. Results Patient responded impressively to high dose steroids. A repeat chest CT nine days after the first one showed a remarkable resolution of the bilateral ground glass opacities. Except for his cardiology medication, no supplemental oxygen neither steroids were prescribed upon his discharge. On one month follow-up, no residual pulmonary dysfunction was noticed with patient preserving a SatO2 of 97–98% on ambient air. Conclusion Vaccine-induced ILD might constitute a rare nCoV-19 post-vaccination adverse-event. According to current restricted data, when post-vaccination ILD is early suspected and recognised, then prompt implementation of steroid treatment reverses significantly the lung lesions without progression to fibrosis.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"692 - 697"},"PeriodicalIF":5.8,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45027215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Changes in testing and incidence of Chlamydia trachomatis and Neisseria gonorrhoeae – the possible impact of the COVID-19 pandemic in the three Scandinavian countries 沙眼衣原体和淋球菌检测和发病率的变化——新冠肺炎大流行对斯堪的纳维亚三国的可能影响

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-09 DOI: 10.1080/23744235.2022.2071461

Lovisa Ivarsson, Magdalena de Arriba Sánchez de la Campa, Karin Elfving, Hong Yin, Karolina Gullsby, L. Stark, Berit Andersen, S. Hoffmann, Å. Gylfe, M. Unemo, B. Herrmann

{"title":"Changes in testing and incidence of Chlamydia trachomatis and Neisseria gonorrhoeae – the possible impact of the COVID-19 pandemic in the three Scandinavian countries","authors":"Lovisa Ivarsson, Magdalena de Arriba Sánchez de la Campa, Karin Elfving, Hong Yin, Karolina Gullsby, L. Stark, Berit Andersen, S. Hoffmann, Å. Gylfe, M. Unemo, B. Herrmann","doi":"10.1080/23744235.2022.2071461","DOIUrl":"https://doi.org/10.1080/23744235.2022.2071461","url":null,"abstract":"Abstract Background This study aimed to investigate what impact the COVID-19 pandemic and its associated restrictions had on Chlamydia trachomatis and Neisseria gonorrhoeae infections in Sweden, Denmark and Norway, countries with very different governmental strategies for handling this pandemic. Methods Retrospective analysis of data collected via requests to Swedish regions and to health authorities in Denmark and Norway. The data were collected for the years 2018–2020 and the data from Sweden were more detailed. Results When the pandemic restrictions were installed in 2020, the number of reported chlamydia cases decreased. The decline was most pronounced in Norway 10.8% (2019: n = 28,446; 2020: n = 25,444) while it was only 3.1% in Denmark (2019: n = 35,688; 2020: n = 34,689) and 4.3% in Sweden (2019: n = 34,726; 2020: n = 33,339). Nucleic acid amplifications tests for chlamydia decreased in Sweden (10%) and Norway (18%) in 2020 compared to 2019, while in Denmark a 21% decrease was noted in April 2020 but thereafter increased to a higher level than 2019. The number of reported gonorrhoea cases decreased in Sweden (17%) and in Norway (39%) in 2020 compared to 2019, while a 21% increase was noted in Denmark. Conclusions Pandemic restrictions had an impact on the number of reported chlamydia infections in all three countries, but only temporarily and did not seem to be correlated to the restriction levels. The number of reported gonorrhoea infections in Sweden and Norway significantly decreased but not in Denmark. Pandemic restrictions appear to have had a limited effect on the spread of chlamydia and gonorrhoea.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"623 - 631"},"PeriodicalIF":5.8,"publicationDate":"2022-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44837712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Cytomegalovirus coinfection in patients with severe acute respiratory syndrome coronavirus 2 infection: a systematic review of reported cases 严重急性呼吸综合征冠状病毒2型感染患者巨细胞病毒合并感染:对报告病例的系统回顾

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-05-06 DOI: 10.1080/23744235.2022.2070273

E. Taherifard, Hamed Movahed, Sima Kiani Salmi, A. Taherifard, S. Abdollahifard, Erfan Taherifard

{"title":"Cytomegalovirus coinfection in patients with severe acute respiratory syndrome coronavirus 2 infection: a systematic review of reported cases","authors":"E. Taherifard, Hamed Movahed, Sima Kiani Salmi, A. Taherifard, S. Abdollahifard, Erfan Taherifard","doi":"10.1080/23744235.2022.2070273","DOIUrl":"https://doi.org/10.1080/23744235.2022.2070273","url":null,"abstract":"Abstract Background Dysfunction of both the innate and the adaptive immune systems is observed in severe coronavirus disease 2019 which, together with administration of immunosuppressive drugs, could lead to cytomegalovirus coinfection or reactivation associated with a poorer outcome. The current study aimed to systematically review the pattern, presentations, clinical course and outcome of patients with severe acute respiratory syndrome coronavirus 2 and cytomegalovirus coinfection. Methods Three online databases, PubMed, Scopus and Web of Science, were searched, and after excluding duplicates and irrelevant reports, eligible articles were identified. Information about patients’ age and gender, comorbidities, presentations of coronavirus disease 2019 and cytomegalovirus, treatment courses and outcomes were extracted. Results A total of 34 reports with 59 patients with coinfection were considered to be eligible for data extraction. A majority of patients were middle-aged or elderly (84.5%). More than three-fourths (79.2%) had at least one comorbidity. Cytomegalovirus viremia was documented in 43 patients. The most common end organ involved was the gastrointestinal tract in 13 patients (48.1% of 27 patients with end organ involvement), mostly as cytomegalovirus colitis, followed by the respiratory tract in 12 patients. There was a significant association between intubation and fatal outcome (p = .011). Conclusion We comprehensively reviewed published cases with coronavirus disease 2019 and cytomegalovirus reactivation. The findings may assist in appraising signs and symptoms for early suspicion, detection and treatment in patients with unusual clinical courses or with severe, prolonged or unexplained deterioration of end organ function.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"543 - 557"},"PeriodicalIF":5.8,"publicationDate":"2022-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45579756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Point prevalence survey to estimate antimicrobial use in a tertiary care university hospital in Pakistan using WHO methodology: findings and implications 使用世卫组织方法估计巴基斯坦三级保健大学医院抗菌药物使用情况的点流行病学调查:结果和影响

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-04-19 DOI: 10.1080/23744235.2022.2064544

M. Sharif, S. Aslam, Z. Saleem

引用次数: 4

Clinical frailty scale as a predictor of disease severity in patients hospitalised with COVID-19 – an observational cohort study 临床虚弱量表作为COVID-19住院患者疾病严重程度的预测因子——一项观察性队列研究

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-04-08 DOI: 10.1080/23744235.2022.2060304

Gustav Mattsson, Margareta Gonzalez Lindh, R. Razmi, Mia Forslin, F. Parenmark, A. Bandert, C. Ehrenborg, A. Palm

{"title":"Clinical frailty scale as a predictor of disease severity in patients hospitalised with COVID-19 – an observational cohort study","authors":"Gustav Mattsson, Margareta Gonzalez Lindh, R. Razmi, Mia Forslin, F. Parenmark, A. Bandert, C. Ehrenborg, A. Palm","doi":"10.1080/23744235.2022.2060304","DOIUrl":"https://doi.org/10.1080/23744235.2022.2060304","url":null,"abstract":"Abstract Background The coronavirus disease 2019 pandemic makes proper resource allocation and prioritisation important. Frailty increases the risk of adverse outcomes and can be quantified using the Clinical frailty scale. The aim of this study was to determine the role of the Clinical frailty scale, in patients ≥65 years of age with coronavirus disease 2019, as a risk factor either for critical coronavirus disease 2019 measured as intensive care unit admission or death or as a risk factor for death. Methods This was a retrospective observational study on patients ≥65 years hospitalised with coronavirus disease 2019 verified by polymerase chain reaction between 5 March 5 and 5 July 2020. The association between Clinical frailty scale and the composite primary outcome intensive care unit admission or death within 30 days post hospitalisation and the secondary outcome death within 30 days post hospitalisation was analysed using multivariable logistic regression models adjusting for gender, age, body mass index, hypertension, and diabetes. Clinical frailty scale was used as a categorical variable (fit score 1–4, frail score 5–6, and severely frail score 7–9). Results In total, 169 patients were included (47.3% women, mean age 79.2 ± 7.8 years). In the fully adjusted model, adjusted odds ratio for intensive care unit admission or death was 1.84 (95%-confidence interval 0.67–5.03, p = .234) for frail and 6.08 (1.70–21.81, p = .006) for severely frail compared to fit patients. For death, adjusted odds ratio was 2.81 (0.89–8.88, p = .079) for frail and 9.82 (2.53–38.10, p = .001) for severely frail compared to fit patients. Conclusions A high Clinical frailty scale score was an independent risk factor for the composite outcome intensive care unit admission or death and for the secondary outcome death.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"583 - 590"},"PeriodicalIF":5.8,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45242572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PIMS-TS immunophenotype: description and comparison with healthy children, Kawasaki disease and severe viral and bacterial infections PIMS-TS免疫表型:与健康儿童、川崎病和严重病毒、细菌感染的描述和比较

IF 5.8 4区医学

Infectious Diseases Pub Date : 2022-04-08 DOI: 10.1080/23744235.2022.2059561

A. García‐Salido, I. Leoz-Gordillo, A. González Brabin, M. Garcia-Teresa, Amelia Martínez-de-Azagra-Garde, M. Iglesias-Bouzas, M. Cabrero-Hernández, G. de Lama Caro-Patón, J. L. Unzueta-Roch, A. Castillo-Robleda, M. Ramírez‐Orellana, M. Nieto-Moro

{"title":"PIMS-TS immunophenotype: description and comparison with healthy children, Kawasaki disease and severe viral and bacterial infections","authors":"A. García‐Salido, I. Leoz-Gordillo, A. González Brabin, M. Garcia-Teresa, Amelia Martínez-de-Azagra-Garde, M. Iglesias-Bouzas, M. Cabrero-Hernández, G. de Lama Caro-Patón, J. L. Unzueta-Roch, A. Castillo-Robleda, M. Ramírez‐Orellana, M. Nieto-Moro","doi":"10.1080/23744235.2022.2059561","DOIUrl":"https://doi.org/10.1080/23744235.2022.2059561","url":null,"abstract":"Abstract Background A new clinical syndrome named Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) has been described. This new disease is a leading cause of hospital and paediatric intensive care unit (PICU). It has been related to immunity dysregulation. Methods Prospective-retrospective observational study to describe the innate cell signature and immunophenotype of children admitted to PICU because of PIMS-TS (from March 2020 to September 2020). The immunophenotype was done through the expression analysis of these proteins of mononuclear cells: CD64, CD18, CD11a and CD11b. They were compared with previous healthy controls and children admitted to PICU because of bacterial infection, viral infection and Kawasaki disease (KD). Two hundred and forty-seven children were studied: 183 healthy controls, 25 viral infections, 20 bacterial infections, 6 KD and 13 PIMS-TS. Results PIMT-TS showed the lowest percentage of lymphocytes and monocytes with higher relative numbers of CD4+ (p = .000). Monocytes and neutrophils in PIMS-TS showed higher levels of CD64 expression (p = .000). Also, CD11a and CD11b were highly expressed (p =,000). Conclusion We observed a differential cell innate signature in PIMS-TS. These findings are consistent with a proinflammatory status (CD64 elevated expression) and lymphocyte trafficking to tissues (CD11a and CD11b). More studies should be carried out to confirm our results.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"54 1","pages":"687 - 691"},"PeriodicalIF":5.8,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45434878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1